Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Early Warning Biomarker Proteins Appear Years or Decades Before Alzheimer’s Disease Symptoms

By LabMedica International staff writers
Posted on 26 May 2021
A large proteomic study linked abnormal blood levels of 38 proteins to higher risks of developing Alzheimer's disease within five years and showed that levels of 16 of these proteins could predict Alzheimer's disease risk two decades in advance.

Investigators at Johns Hopkins University (Baltimore, MD, USA) speculated that the plasma proteomic changes that precede the onset of dementia could yield insights into disease biology and highlight new biomarkers and avenues for diagnosis and intervention. To confirm this theory, they collaborated with researchers at the bio-technology company SomaLogic (Boulder, CO, USA) using the recently developed SomaScan technology for protein classification.

Initially, the investigators analyzed blood samples taken during 2011-13 from more than 4,800 late-middle-aged participants in the Atherosclerosis Risk in Communities (ARIC) study, a large epidemiological study of heart disease-related risk factors and outcomes that began in 1985. SomaScan was used to determine levels of nearly 5,000 distinct proteins in the banked ARIC samples. SomaScan was then used to measure protein levels from more than 11,000 blood samples taken from much younger ARIC participants in 1993-95.

Results of the first part of the study revealed 38 proteins whose abnormal levels were significantly associated with a higher risk of developing Alzheimer's disease in the five years following the blood draw. Additional data obtained during the second part of the study revealed that abnormal levels of 16 of the 38 previously identified proteins were associated with the development of Alzheimer's disease in the nearly two decades between that blood draw and a follow-up clinical evaluation in 2011-13.

Further in-depth analysis of the data causally implicated two dementia-associated proteins (SVEP1 and angiostatin) in Alzheimer’s disease. SVEP1, an immunologically relevant cellular adhesion protein, was found to be part of larger dementia-associated protein networks, and circulating levels were associated with atrophy in brain regions, such as the CA3 area of the hippocampus, which are vulnerable to Alzheimer’s disease pathology.

"This is the most comprehensive analysis of its kind to date, and it sheds light on multiple biological pathways that are connected to Alzheimer's," said senior author Dr. Josef Coresh, professor of epidemiology at Johns Hopkins University. "Some of these proteins we uncovered are just indicators that disease might occur, but a subset may be causally relevant, which is exciting because it raises the possibility of targeting these proteins with future treatments."

The study was published in the May 14, 2021, online edition of the journal Nature Aging.

Related Links:
Johns Hopkins University
SomaLogic



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.